​CEMPRA INC. 

​Securities Class Action

Class Period
May 1, 2016 to November 1, 2016
Lead Plaintiff Motion Deadline
January 3, 2017
Stock Symbol
CEMP
Court
Middle District of North Carolina


FREE CASE EVALUATION

Email us OR fill out the form below for a free case evaluation





​​The FDA reported that “[a] significant safety signal for hepatotoxicity was observed in the solithromycin development program,” and there was concern for “the high rate of infusion site-related reactions.”
​On this news, Cempra stock price fell $11.35, or 60.86%, to close at $7.30 on November 2, 2016.

About this action:​ A class action has been commenced in the United States District Court for the Middle District of North Carolina on behalf of purchasers of Cempra Inc. (“Cempra”) (NASDAQ: CEMP) securities between May 1, 2016 and November 1, 2016  (the “Class Period”) .

​If you wish to serve as lead plaintiff, you must move the Court no later than January 3, 2017.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

​If you would like more information about getting involved in the Cempra Class Action, please fill out the form to the left, or contact Sheila Feerick at 1-800-221-0015, or email

info@SafirsteinMetcalf.com.  Safirstein Metcalf LLP represents individual and institutional clients in a wide variety of litigation, with an emphasis on class, derivative, and other complex actions on behalf of investors and consumers. The firm handles matters on a contingency fee basis.Cempra is a clinical-stage pharmaceutical company which focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America.  One of its lead product candidates is solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community acquired bacterial pneumonia, as well as for uncomplicated bacterial urethritis.

The Complaint alleges that throughout the Class Period, defendants issued false and misleading statements to investors and/or failed to disclose that: (1) solithromycin posed significant safety risks for hepatotoxicity; and (2) as a result of the foregoing, Cempra’s public statements were materially false and misleading at all relevant times.

On November 2, 2016, the United States Food and Drug Administration (“FDA”) posted on its website a briefing document addressing solithromycin.  The FDA reported that “[a] significant safety signal for hepatotoxicity was observed in the solithromycin development program,” and there was concern for “the high rate of infusion site-related reactions.”  On this news, Cempra stock fell $11.35, or 60.86%, to close at $7.30 on November 2, 2016.  On November 4, 2016, Cempra issued a press release announcing that NASDAQ has halted trading of the Company’s common stock.  Cempra also announced that the FDA Antimicrobial Drugs Advisory Committee (“AMDAC”) would meet that day to discuss the safety and efficacy of solithromycin to treat community-acquired bacterial pneumonia.